Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Daniela Krummenacher

Wolfgang Wostl

Hans Iding

Beat Wirz

Synese Jolidon

Andrew William Thomas

Rene Wyler

Rosa Maria Rodriguez-Sarmiento

Hasane Ratni

Werner Neidhart

Juergen Wichmann

Roland Jakob-Roetne

Guido Galley

Daniel Hunziker

Anja Limberg

Rosa Maria Rodriguez Sarmiento

Cosimo Dolente

Bjoern Bartels

Annick Goergler

Michael Reutlinger

Christian Schnider

Piergiorgio Francesco Tommaso Pettazzoni

David Stephen Hewings

Stefan Berchtold

Roland Jakob-roetne

The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.

Methylquinazolinone derivatives

The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein Ris hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two Roccur; Ris lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH-heterocycloalkyl unsubstituted or substituted by lower alkyl; Ris halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)-lower alkyl; n is 1, 2 or 3; if n is &#x3e;1, then Rmay be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Phenoxytriazoles

The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease which is mediated by a monoamine oxidase B inhibitor, in particular Alzheimer's disease and senile dementia.

4-pyrrolidino-phenyl-benzyl ether derivatives

The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R, R, Rand Rare as defined in the description and claims.

Process for the preparation of enantiopure pyrrolidin-2-one derivatives

The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.

4-Pyrrolidino-phenyl-benzyl ether derivatives

Growing community of inventors

Rheinfelden, Switzerland

Daniela Krummenacher